December 16, 2015 Clinical trials are too white, with less than 2 percent of cancer studies including enough minority people to provide information that could be useful for health, a study finds.
<iframe src="http://www.npr.org/player/embed/459666750/459985226" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Glenn Lightner in 2012 at age 13. His father searched clinicaltrials.gov for years, to no avail, hoping to find a promising experimental cancer treatment that might save his son's life.
Courtesy of Lawrence Lightner
March 11, 2015 Federal law requires publicly funded medical researchers to promptly report the results of many experimental treatments. But few are doing so, a review shows, and patients may be hurt.
<iframe src="http://www.npr.org/player/embed/392355433/392375506" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Nurses assist a new patient at an Ebola center in Liberia's Lofa County. As drug trials get underway, patients may receive experimental medicines.
November 11, 2014 Can you run a clinical trial without a placebo group? That's one of the questions facing researchers in West Africa.
<iframe src="http://www.npr.org/player/embed/363054794/363214541" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
October 1, 2012 Commentator Stuart Kauffman says we need to invent new techniques to investigate multi-factorial causality in medicine. It's the second in a series of posts that will dive into this topic.
NPR thanks our sponsors
Become an NPR sponsor